(BCRX) BioCryst Pharmaceuticals - Ratings and Ratios
Oral Pill,Hereditary Swelling,Angioedema Therapy
BCRX EPS (Earnings per Share)
BCRX Revenue
Description: BCRX BioCryst Pharmaceuticals
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) is a biotechnology company listed on the NASDAQ exchange. As a common stock, it is subject to the volatility and liquidity characteristics of the US equity market.
The stock has multiple support levels, ranging from $6.1 to $8.0, indicating potential areas where the stock price may stabilize or bounce back. These levels can be crucial in determining the stocks risk profile and potential entry or exit points for traders.
From a fundamental analysis perspective, BioCryst Pharmaceuticals has a market capitalization of approximately $1.74 billion, categorizing it as a mid-cap stock. The forward Price-to-Earnings (P/E) ratio is 128.21, suggesting that investors are pricing in significant future earnings growth. However, the current P/E ratio is 0.00, indicating that the company is currently not profitable or has negative earnings.
Key economic drivers for BioCryst Pharmaceuticals include the development and commercialization of its pharmaceutical products, particularly in the biotechnology sector. The companys revenue growth, pipeline progress, and eventual profitability will be crucial in driving the stock price. Investors should monitor the companys research and development (R&D) expenses, sales and marketing efforts, and cash burn rate to gauge its path to profitability.
To evaluate the stocks performance, investors can track Key Performance Indicators (KPIs) such as revenue growth rate, R&D pipeline progress, cash runway, and regulatory milestones. Additionally, monitoring the companys guidance, managements commentary on earnings calls, and industry trends can provide valuable insights into the stocks potential direction.
The biotechnology sector is known for its high-risk, high-reward nature, and BioCryst Pharmaceuticals is not immune to this. The companys stock price can be influenced by factors such as clinical trial results, FDA approvals, and competitor activity. As such, investors should be prepared for potential volatility and adjust their investment strategies accordingly.
BCRX Stock Overview
| Market Cap in USD | 1,660m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 1994-03-03 |
BCRX Stock Ratings
| Growth Rating | -17.1% |
| Fundamental | 69.0% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -18.1% |
| Analyst Rating | 4.42 of 5 |
BCRX Dividends
Currently no dividends paidBCRX Growth Ratios
| Growth Correlation 3m | -85.2% |
| Growth Correlation 12m | 58.6% |
| Growth Correlation 5y | -41.7% |
| CAGR 5y | -17.38% |
| CAGR/Max DD 3y | -0.25 |
| CAGR/Mean DD 3y | -0.38 |
| Sharpe Ratio 12m | -0.57 |
| Alpha | -14.70 |
| Beta | 0.613 |
| Volatility | 49.33% |
| Current Volume | 3123.7k |
| Average Volume 20d | 2275.6k |
| Stop Loss | 7.4 (-3.9%) |
| Signal | -1.37 |
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income (-35.7m TTM) > 0 and > 6% of Revenue (6% = 33.5m TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA 24.05pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 39.69% (prev 61.32%; Δ -21.63pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.04 (>3.0%) and CFO 16.8m > Net Income -35.7m (YES >=105%, WARN >=100%) |
| Net Debt (650.4m) to EBITDA (63.4m) ratio: 10.25 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.25 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (219.9m) change vs 12m ago 6.52% (target <= -2.0% for YES) |
| Gross Margin 97.00% (prev 98.30%; Δ -1.30pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 119.9% (prev 80.91%; Δ 39.03pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 0.66 (EBITDA TTM 63.4m / Interest Expense TTM 94.4m) >= 6 (WARN >= 3) |
Altman Z'' -10.62
| (A) 0.48 = (Total Current Assets 398.5m - Total Current Liabilities 177.2m) / Total Assets 457.2m |
| (B) -3.86 = Retained Earnings (Balance) -1.76b / Total Assets 457.2m |
| warn (B) unusual magnitude: -3.86 — check mapping/units |
| (C) 0.13 = EBIT TTM 62.2m / Avg Total Assets 464.8m |
| (D) -2.00 = Book Value of Equity -1.76b / Total Liabilities 878.8m |
| Total Rating: -10.62 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 68.97
| 1. Piotroski 4.50pt = -0.50 |
| 2. FCF Yield 0.74% = 0.37 |
| 3. FCF Margin 2.83% = 0.71 |
| 4. Debt/Equity data missing |
| 5. Debt/Ebitda 11.51 = -2.50 |
| 6. ROIC - WACC 9.18% = 11.48 |
| 7. RoE data missing |
| 8. Rev. Trend 95.94% = 4.80 |
| 9. Rev. CAGR 32.19% = 2.50 |
| 10. EPS Trend 84.48% = 2.11 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of BCRX shares?
Over the past week, the price has changed by -5.98%, over one month by -8.00%, over three months by -25.17% and over the past year by -2.65%.
Is BioCryst Pharmaceuticals a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BCRX is around 6.51 USD . This means that BCRX is currently overvalued and has a potential downside of -15.45%.
Is BCRX a buy, sell or hold?
- Strong Buy: 6
- Buy: 5
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BCRX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 17.2 | 123.4% |
| Analysts Target Price | 17.2 | 123.4% |
| ValueRay Target Price | 7.2 | -6.1% |
Last update: 2025-09-16 04:31
BCRX Fundamental Data Overview
CCE Cash And Equivalents = 260.5m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 21.978
P/S = 2.9784
P/B = 56.5858
P/EG = -0.28
Beta = 1.131
Revenue TTM = 557.5m USD
EBIT TTM = 62.2m USD
EBITDA TTM = 63.4m USD
Long Term Debt = 690.6m USD (from longTermDebt, last quarter)
Short Term Debt = 39.8m USD (from shortTermDebt, last quarter)
Debt = 730.4m USD (Calculated: Short Term 39.8m + Long Term 690.6m)
Net Debt = 650.4m USD (from netDebt column, last quarter)
Enterprise Value = 2.13b USD (1.66b + Debt 730.4m - CCE 260.5m)
Interest Coverage Ratio = 0.66 (Ebit TTM 62.2m / Interest Expense TTM 94.4m)
FCF Yield = 0.74% (FCF TTM 15.8m / Enterprise Value 2.13b)
FCF Margin = 2.83% (FCF TTM 15.8m / Revenue TTM 557.5m)
Net Margin = -6.41% (Net Income TTM -35.7m / Revenue TTM 557.5m)
Gross Margin = 97.00% ((Revenue TTM 557.5m - Cost of Revenue TTM 16.7m) / Revenue TTM)
Tobins Q-Ratio = -1.21 (set to none) (Enterprise Value 2.13b / Book Value Of Equity -1.76b)
Interest Expense / Debt = 2.95% (Interest Expense 21.6m / Debt 730.4m)
Taxrate = 21.60% (1.40m / 6.49m)
NOPAT = 48.7m (EBIT 62.2m * (1 - 21.60%))
Current Ratio = 2.25 (Total Current Assets 398.5m / Total Current Liabilities 177.2m)
Debt / EBITDA = 11.51 (Net Debt 650.4m / EBITDA 63.4m)
Debt / FCF = 46.34 (Debt 730.4m / FCF TTM 15.8m)
Total Stockholder Equity = -454.5m (last 4 quarters mean)
RoA = -7.81% (Net Income -35.7m, Total Assets 457.2m )
RoE = unknown (Net Income TTM -35.7m / Total Stockholder Equity -454.5m)
RoCE = 26.32% (Ebit 62.2m / (Equity -454.5m + L.T.Debt 690.6m))
RoIC = 15.64% (NOPAT 48.7m / Invested Capital 311.7m)
WACC = 6.45% (E(1.66b)/V(2.39b) * Re(8.27%)) + (D(730.4m)/V(2.39b) * Rd(2.95%) * (1-Tc(0.22)))
Shares Correlation 3-Years: 100.00 | Cagr: 1.52%
Discount Rate = 8.27% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 71.60% ; FCFE base≈15.8m ; Y1≈11.4m ; Y5≈6.31m
Fair Price DCF = 0.55 (DCF Value 115.8m / Shares Outstanding 209.9m; 5y FCF grow -32.68% → 3.0% )
Revenue Correlation: 95.94 | Revenue CAGR: 32.19%
Rev Growth-of-Growth: 16.15
EPS Correlation: 84.48 | EPS CAGR: 0.0%
EPS Growth-of-Growth: 105.2
Additional Sources for BCRX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle